The University of Southampton
University of Southampton Institutional Repository

Factors influencing success in endoscopic treatment of grade 4-5 primary Vesicoureteric Reflux (VUR) in infancy and childhood

Factors influencing success in endoscopic treatment of grade 4-5 primary Vesicoureteric Reflux (VUR) in infancy and childhood
Factors influencing success in endoscopic treatment of grade 4-5 primary Vesicoureteric Reflux (VUR) in infancy and childhood

Introduction: there is equipoise among pediatric urologists regarding endoscopic versus surgical intervention for symptomatic Grade 4-5 Vesicoureteric Reflux (VUR), particularly in infancy. Our aim was to assess outcomes of first-line endoscopic treatment in all cases of symptomatic Grade 4-5 VUR and we hypothesised that using endoscopic Dx/HA as first line management for primary VUR would obviate the need for ureteric reimplantation in the majority of cases. 

Methods: retrospective single-surgeon analysis of consecutive patients with primary Grade 4-5 VUR over 15 years. Indication for intervention was breakthrough UTI on prophylaxis. Endoscopic dextranomer/hyaluronic acid co-polymer (Dx/HA; Deflux®) injection was first-line procedure. Primary outcomes were both post-procedure febrile culture positive urinary tract infection (UTI) and VUR recurrence on post-operative VCUG requiring further surgical intervention. We postulated that risk factors influencing outcome are: age under 1 year, female gender, postnatal versus antenatal presentation, duplex anatomy, circumcision status and presence of congenital uptake defects on DMSA. Data analysed using Fisher's Exact Test/Multivariate Analysis. 

Results: 77 patients with Grade 4-5 VUR were identified, of whom 49 (11 bilateral) underwent a Dx/HA injection at median 12 (3-84) months. Median follow-up post-injection was 32 (2–145) months. There were no reported complications or ureteral obstruction. Sixteen (33 %) patients suffered a febrile UTI at follow-up; on further investigation, half (8/16) of these were found to have recurrent VUR. Therefore 67 % were symptom free and 84 % did not require further intervention after one injection (41/49), and 98 % after further injections (48/49). Duplex systems had a similar outcome of 80 % not requiring further intervention. On multivariate analysis, males were found to have a significantly better outcome than females (p < 0.015) irrespective of circumcision status. Forty-one percent of the children in our cohort had uptake defects on DMSA prior to intervention, but this did not have any difference on outcome. Conclusion: Endoscopic Dx/HA injection is a safe first-line, day-case treatment for Grade 4-5 VUR in children of any age, with a low complication rate. Two-thirds of patients are asymptomatic after one injection; 84 % do not require further procedures after one injection, and 98 % after 2 injections.

Deflux injection, Dextranomer hyaluronic acid, Endoscopic injection, Endoscopic treatment, Hydrodistension, Renal scarring, Subureteric injection, Urinary tract infection, VUR children, Vesicoureteral reflux, Vesicoureteric reflux
0022-3468
Tiboni, Sonia G.
de3663a4-0685-4bba-9cff-5b63f8c9e362
Bethell, George S.
c7a62cc1-5573-41f6-ae00-3c11e8219dd4
Davidson, Joseph R.
b3ad4bdf-41e0-4af1-a2b5-2c65cd72b6ae
Farrugia, Marie-Klaire
97b4bf3c-23d4-4640-8a48-970f4c99ebfd
Tiboni, Sonia G.
de3663a4-0685-4bba-9cff-5b63f8c9e362
Bethell, George S.
c7a62cc1-5573-41f6-ae00-3c11e8219dd4
Davidson, Joseph R.
b3ad4bdf-41e0-4af1-a2b5-2c65cd72b6ae
Farrugia, Marie-Klaire
97b4bf3c-23d4-4640-8a48-970f4c99ebfd

Tiboni, Sonia G., Bethell, George S., Davidson, Joseph R. and Farrugia, Marie-Klaire (2025) Factors influencing success in endoscopic treatment of grade 4-5 primary Vesicoureteric Reflux (VUR) in infancy and childhood. Journal of Pediatric Surgery, 60 (3), [162157]. (doi:10.1016/j.jpedsurg.2025.162157).

Record type: Article

Abstract

Introduction: there is equipoise among pediatric urologists regarding endoscopic versus surgical intervention for symptomatic Grade 4-5 Vesicoureteric Reflux (VUR), particularly in infancy. Our aim was to assess outcomes of first-line endoscopic treatment in all cases of symptomatic Grade 4-5 VUR and we hypothesised that using endoscopic Dx/HA as first line management for primary VUR would obviate the need for ureteric reimplantation in the majority of cases. 

Methods: retrospective single-surgeon analysis of consecutive patients with primary Grade 4-5 VUR over 15 years. Indication for intervention was breakthrough UTI on prophylaxis. Endoscopic dextranomer/hyaluronic acid co-polymer (Dx/HA; Deflux®) injection was first-line procedure. Primary outcomes were both post-procedure febrile culture positive urinary tract infection (UTI) and VUR recurrence on post-operative VCUG requiring further surgical intervention. We postulated that risk factors influencing outcome are: age under 1 year, female gender, postnatal versus antenatal presentation, duplex anatomy, circumcision status and presence of congenital uptake defects on DMSA. Data analysed using Fisher's Exact Test/Multivariate Analysis. 

Results: 77 patients with Grade 4-5 VUR were identified, of whom 49 (11 bilateral) underwent a Dx/HA injection at median 12 (3-84) months. Median follow-up post-injection was 32 (2–145) months. There were no reported complications or ureteral obstruction. Sixteen (33 %) patients suffered a febrile UTI at follow-up; on further investigation, half (8/16) of these were found to have recurrent VUR. Therefore 67 % were symptom free and 84 % did not require further intervention after one injection (41/49), and 98 % after further injections (48/49). Duplex systems had a similar outcome of 80 % not requiring further intervention. On multivariate analysis, males were found to have a significantly better outcome than females (p < 0.015) irrespective of circumcision status. Forty-one percent of the children in our cohort had uptake defects on DMSA prior to intervention, but this did not have any difference on outcome. Conclusion: Endoscopic Dx/HA injection is a safe first-line, day-case treatment for Grade 4-5 VUR in children of any age, with a low complication rate. Two-thirds of patients are asymptomatic after one injection; 84 % do not require further procedures after one injection, and 98 % after 2 injections.

Text
VUR Final accepted version - Accepted Manuscript
Restricted to Repository staff only until 6 January 2026.
Request a copy

More information

Accepted/In Press date: 1 January 2025
e-pub ahead of print date: 6 January 2025
Published date: March 2025
Keywords: Deflux injection, Dextranomer hyaluronic acid, Endoscopic injection, Endoscopic treatment, Hydrodistension, Renal scarring, Subureteric injection, Urinary tract infection, VUR children, Vesicoureteral reflux, Vesicoureteric reflux

Identifiers

Local EPrints ID: 501068
URI: http://eprints.soton.ac.uk/id/eprint/501068
ISSN: 0022-3468
PURE UUID: 593b6820-90b7-445a-8978-4b347b0e2a02
ORCID for George S. Bethell: ORCID iD orcid.org/0000-0002-1302-0735

Catalogue record

Date deposited: 22 May 2025 16:37
Last modified: 23 May 2025 02:06

Export record

Altmetrics

Contributors

Author: Sonia G. Tiboni
Author: George S. Bethell ORCID iD
Author: Joseph R. Davidson
Author: Marie-Klaire Farrugia

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×